A Clinical Evaluation of Dhatrayadi Ghrita Uttarbasti and Latakaranja Ghanavati in the Management of Anovulatory Infertility

Efficacy Of Dhatrayadi Ghrita Uttar Basti Combined With Latakaranja Ghanavati Orally In The Management Of Infertility Due To Anovulation An Exploratory Study - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096637

Enrollment

Registered

2025-10-30

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N970- Female infertility associated withanovulation Health Condition 2: N970- Female infertility associated withanovulation Health Condition 3: N970- Female infertility associated withanovulation

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Married Women aged 20 to 35 years in reproductive age group Diagnosed with anovulatory infertility confirmed by TVS Regular or irregular cycles with confirmed absence of ovulation Normal uterine cavity and tubal patency HSG or laparoscopy Partner with normal semen analysis Those patients who are eligible for Basti karma Provided written informed consent

Exclusion criteria

Exclusion criteria: Tubal blockage, uterine anomalies or endometriosis Uncontrolled endocrine and Metabolic disorders Acute PID Severe systemic illness diabetes hypertension hepatic renal disorders Tuberculosis Concurrent use of other fertility treatments or hormone therapy Pregnant or lactating women History of pelvic surgery affecting reproductive organs Those patients who are not eligible for Basti karma Patient on Metformin and other insuline sensitizing medication Rosiglitazone Pioglitazone Patient on Clomiphene citrate or estrogen modulators

Design outcomes

Primary

Measure	Time frame
Follicular Development Ovarian Volume and Ovulation Assessed By Transvaginal Sonographic TVS Follicular MonitoringTimepoint: Within 2 weeks prior to treatment start and Day 2 3 after menses	—

Secondary

Measure	Time frame
Regularisation of the menstrual cycle Endometrial thickness Hormonal profile changes Conception status this secondary outcomeTimepoint: Each cycle (Cycle 1–3) end of treatment (Week 12) follow-up (Week 24) (Day 2–3) mid-cycle Day 12–14 of each cycle end of treatment (Week 12) optional follow-up (Week 16–18) (Day 2–3) optional mid-cycle Cycle 2 (Day 14) post-treatment (Week 12) follow-up (Week 24) Each treatment cycle end of treatment (Week 12) follow up (Week 24)	—

Measure

Time frame

Regularisation of the menstrual cycle Endometrial thickness Hormonal profile changes Conception status this secondary outcomeTimepoint: Each cycle (Cycle 1–3) end of treatment (Week 12) follow-up (Week 24) (Day 2–3) mid-cycle Day 12–14 of each cycle end of treatment (Week 12) optional follow-up (Week 16–18) (Day 2–3) optional mid-cycle Cycle 2 (Day 14) post-treatment (Week 12) follow-up (Week 24) Each treatment cycle end of treatment (Week 12) follow up (Week 24)

—

Countries

India

Contacts

Public ContactDr Meenakshi Pandey

All Inddia Institute of Ayurveda

drmeenakshipathak@gmail.com9984549998

Outcome results